RxDoctor Payments Data

Ari Ciment, MD

Pulmonary Disease · Miami Beach, FLNPI 1932261542

Payments from drug & device makers

$24,147in general payments, 2019–2025

Across 251 payments — averaging $96.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vapotherm Inc$15K
  • Mylan Specialty L.p.$5K
  • GSK$2K
  • AstraZeneca$622
  • Actelion Pharmaceuticals US, Inc.$571
  • AbbVie$320
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$14,40560%
  • Speaking & faculty fees$4,56819%
  • Food & beverage$5,00721%
  • Education$1681%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,147 in reported general payments places this provider in the 75th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$153,507
Medicare patients
404
Services billed
1,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZemairaAlpha-1-Proteinase Inhibitor14$113,331
Trelegy ElliptaFluticasone/Umeclidin/Vilanter105$88,577
Breztri AerosphereBudesonide/Glycopyr/Formoterol45$31,328
Breo ElliptaFluticasone/Vilanterol33$15,048
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$11,766
SymbicortBudesonide/Formoterol Fumarate19$4,797
Ventolin HfaAlbuterol Sulfate28$1,731
Albuterol Sulfate HfaAlbuterol Sulfate73$1,420
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$1,197
Wixela InhubFluticasone Propion/Salmeterol12$632
Methylprednisolone56$538
Azelastine Hcl19$524
Fluticasone Propionate18$317
Azithromycin66$309
Doxycycline Hyclate22$195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,574$115,391161 claims
AstraZenecaBreztri Aerosphere, Symbicort$622$36,12564 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →